WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 9, 318-328. Review Article ISSN 2277–7105

THE MARKET SURVEY OF CEFTRIAXONE

Naveen Prakash*, Devasish Jena, Manoj Prajapati, Shivam Yadav

SN College of Pharmacy Babupur Jaunpur.

Article Received on
09 March 2025,

Revised on 29 March 2025,
Accepted on 19 April 2025

DOI: 10.20959/wjpr20259-36400

***Corresponding Author**
Naveen Prakash
SN College of Pharmacy
Babupur Jaunpur.

ABSTRACT

Pharmaceutical marketing is an important aspect of promoting healthcare products and services to healthcare professionals, patients, and consumers. Pharmaceutical marketing is the strategic promotion, advertising, and selling of pharmaceutical products, such as prescription and over- the-counter drugs, vaccines, and medical devices. Successful pharmaceutical marketing ensures that patients are well-informed, healthcare professionals are well-informed, and pharmaceutical companies are successful in a competitive marketplace. This abstract gives an overview of pharmaceutical marketing, its definition, objectives, and main components Pharmaceutical marketing is a niche area of marketing that entails the promotion of drugs and medical equipment to healthcare providers, patients, and other players in the healthcare system. Pharmaceutical marketing is a key function in the pharmaceutical sector by affecting prescribing behavior, patient awareness, and overall healthcare outcomes. The overall objective of drug marketing is to maximize exposure and sales for pharmaceutical products without deviating from stringent ethical, legal, and regulatory standards. Another attribute of drug marketing is its use of a double audience. In contrast to most consumer goods, drugs are prescribed by physicians but taken by patients. Therefore, drug companies need to develop marketing strategies that clearly convey benefits, effectiveness, and safety to both parties. For doctors, the focus is on scientific data, clinical trial results, and continuing medical education . For patients, messages are more likely to emphasize symptom relief, improvement in quality of life, and emotional appeal. Direct-to-consumer advertising.

KEYWORDS: Introduction, Drug Profile, Market Survey, Summery, Conclusion.

INTRODUCTION

Pharma Marketing

Pharmaceutical marketing is a vibrant and specialized area that focuses on the promotion, distribution, and sale of pharmaceutical products, which include prescription medications, over- the-counter (OTC) drugs, and healthcare services. The primary aim of pharma marketing is to raise awareness about treatments, educate healthcare professionals (HCPs) and patients regarding available options, and ultimately boost sales while adhering to ethical standards and regulatory requirements.

Pharmaceutical marketing is a crucial aspect of the healthcare industry, enabling pharmaceutical companies to promote their products, educate healthcare professionals, and ultimately improve patient outcomes**.**

Pharmaceutical marketing stands apart from other industries due to the distinct nature of healthcare, where the emphasis is not solely on selling a product but also on enhancing patient outcomes and supporting public health. Strategies in pharmaceutical marketing must comply with stringent regulations established by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which ensure that marketing practices do not mislead patients or healthcare providers and that public safety is prioritized.

Types of Pharmaceutical Marketing

1. **Prescription drug marketing:** Targeted towards healthcare professionals to promote prescription medications.
2. **Over-the-counter (OTC) marketing**: Targeted towards consumers to promote non-prescription medications.
3. **Digital marketing:** Utilizes online platforms, such as social media, email, and websites, to promote pharmaceutical products.
4. **Medical representative marketing**: Involves face-to-face interactions between medical representatives and healthcare professionals.
5. **Clinical Trials and Research**: Clinical trials and the results from scientific studies can play a significant role in marketing strategies. Companies highlight the safety and efficacy of their products based on real-world evidence.

Objectives

1. **Increase brand awareness:** Establish recognition and preference for pharmaceutical products.
2. ***Drive sales:*** *Encourage healthcare professionals to prescribe and patients to request specific medications.*
3. **Educate healthcare professionals:** Provide **information on safety, efficacy, and proper use of pharmaceutical products.**
4. **Support disease awareness:** Educate patients and healthcare professionals about specific diseases and treatment options.

Key Components

1. **Product promotion**: Highlighting the benefits, features, and unique selling points of pharmaceutical products.
2. **Targeted advertising:** Reaching healthcare professionals, patients, and consumers through various media channels.
3. **Sales strategies:** Employing tactics to persuade healthcare professionals to prescribe and patients to request specific medications**.**
4. **Market research:** Analyzing market trends, competitor activity, and customer needs to inform marketing strategies.

Trends and Future Directions

1. **Increased focus on digital marketing**: Growing importance of online platforms in pharmaceutical marketing.
2. **Personalized medicine and targeted marketing:** Use of genetic and biomarker data to tailor marketing efforts.
3. **Patient-centric marketing**: Greater emphasis on patient needs, preferences, and outcomes.
4. **Real-world evidence and data analytics:** Use of real-world data to inform marketing strategies and measure effectiveness.

DRUG PROFILE CEFTRIAXONE

Ceftriaxone is used to treat bacterial infections in many different parts of the body. This medicine is also given before certain types of surgery to prevent infections. Ceftriaxone belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth.

DIAGRAM



Chemical Formula - C18H16N8Na2O7S3

INTRODUCED

Ceftriaxone, developed by Hoffmann-La Roche and patented in 1978, was **approved by FDA in 1984** and marketed under the brand name **Rocephin** as a third-generation cephalosporin antibiotic to treat bacterial infections, exemplified by endocarditis, pneumonia, middle ear infections, skin infections, and urinary tract.

Brand Names Rocephin

Generic Name Ceftriaxon

1. **Mechanism of Action**: Ceftriaxone works by inhibiting bacterial cell wall synthesis, which leads to cell lysis and death. It binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane, disrupting the structural integrity of the cell wall. This ultimately results in the destruction of the bacteria.

Binding to Penicillin-Binding Proteins (PBPs): Ceftriaxone binds to and acts against certain enzymes known as penicillin-binding proteins (PBPs) present in the bacterial cell wall. These enzymes are implicated in the last steps of peptidoglycan synthesis, which is an essential component of the bacterial cell wall.

Inhibition of Cell Wall Synthesis: By binding to PBPs, ceftriaxone inhibits the cross-linking of the peptidoglycan molecules in the bacterial cell wall. This compromises the wall structure, making it incapable of withstanding osmotic pressure.

Bacterial Lysis: The inability to maintain an intact cell wall makes the bacterial cell unstable and results in cell lysis, or rupture, due to the osmotic imbalance.

Bactericidal Action: Due to its action on cell wall integrity, ceftriaxone is bactericidal, that is, it kills bacteria instead of just inhibiting their growth.

2. INDICATION

Respiratory Infections: Including pneumonia (caused by Streptococcus pneumoniae, Haemophilus influenzae).

Urinary Tract Infections (UTIs): Caused by organisms such as Escherichia coli**.**

Meningitis: Especially effective against Neisseria meningitidis and Streptococcus pneumoniae.

Sepsis: Caused by a variety of Gram-negative and Gram-positive bacteria.

Skin and Soft Tissue Infections: Including cellulitis and abscesses.

Gonorrhea: An effective treatment for gonorrheal infections.

Intra-abdominal Infections: When combined with other antibiotics**.**

3. Dosage and Administration

Ceftriaxone is usually given either through an intravenous (IV) line or via intramuscular (IM) injection, based on the patient's clinical condition and overall health. The dosage can differ depending on the type of infection being treated, as well as the patient's age, weight, and kidney function

Adult - doses range from 1 to 2 grams per day Neonates - 50 mg/kg/day

4. Side Effects

Common side effects may include **rash, diarrohea, nausea, and allergic reactions**. More serious side effects can involve **anaphylaxis, blood clotting disorders, liver dysfunction, and gallbladder** sludge (which can be reversed). Ceftriaxone should be administered with caution in patients who have **renal or hepatic impairment**.

5. **Allergy to Beta-lactam Antibiotics:** Individuals with a severe allergy to penicillins or cephalosporins should steer clear of ceftriaxone.

Neonates: Caution is advised when using ceftriaxone in neonates, especially those with hyperbilirubinemia, as there is a risk of bilirubin encephalopathy.

Drug Interactions: Ceftriaxone can interact with specific medications, such as calcium-containing intravenous solutions, which may lead to the formation of precipitates.

6. **Resistance:** Although ceftriaxone is effective against many types of bacteria, resistance can develop, especially due to the production of extended-spectrum beta-lactamases (ESBLs) or other mechanisms. In these situations, alternative antibiotics may be necessary.

MARKET SURVEY

MECHANISM OF ACTION CEFTRIAXONE

Cell Wall Synthesis Inhibition

Ceftriaxone binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane. Prevents cross-linking of peptidoglycan chains, compromising the bacterial cell wall **Penicillin-Binding Proteins (PBPs).**

A group of enzymes that are involved in the terminal steps of bacterial cell wall synthesis. By binding to PBPs, ceftriaxone inhibits their activity, leading to poor cell wall integrity.

Pharmacokinetics

Absorption

Administered by intravenous and intramuscular routes.

Distribution

Widely distributed in body tissues and fluids, including the cerebrospinal fluid.

Elimination

Primarily cleared by kidneys.

SYMPTOM

Gastrointestinal issues: Diarrhea, upset stomach, or vomiting

Injection site reactions: Pain, tenderness, hardness, or warmth at the injection site.

Allergic reactions: Rash, itching, or swelling, especially of the face/tongue/throat.

Changes in blood counts: Eosinophilia (increased eosinophils), leukopenia (decreased white blood cells), thrombocytopenia (decreased platelets)

Neurotoxicity: Symptoms may include seizures, altered mental status, or coma, particularly in patients with renal impairment or the elderly.

ARVERSE EFFECT

1 Common Adverse Effects

Fatigue: Perhaps the most common side effect of docetaxe

Nausea and Vomiting: Expected following chemotherapy, though these can be controlled with medications.

Hair Loss (Alopecia): This is temporary hair loss associated with docetaxel treatment. Decreased Appetite: Patients might have less hunger.

Diarrohea: Gastrointestinal side effects are typical with chemotherapy drugs. Mouth Sores: Inflammation of the mouth or mouth sores may develop.

2 Serious Adverse Effects

Bone Marrow Suppression: Docetaxel may cause neutropenia (reduced white blood cell count), anemia, and thrombocytopenia (reduced platelet count), which may contribute to infections, bleeding, and fatigue.

Infection: Because of its effect on the immune system, docetaxel may contribute to infections. Toxicity to the Liver: In a few instances, liver function may be impaired, resulting in jaundice (yellow discoloration of the skin and eyes), raised levels of liver enzymes, or liver failure.

Fluid Retention: Docetaxel may cause excessive fluid retention, leading to swelling in hands and feet or other areas of the body. This may result in more severe conditions such as pleural effusion (fluid collection around the lungs).

Allergic Reactions: Certain patients might have extreme allergic reactions such as anaphylaxis, which may result in shortness of breath, facial and throat swelling, and fast heart rate.

Neuropathy: Numbness, pain, or tingling in hands and feet could be experienced (peripheral neuropathy).

Problems of Heart: Occasionally, docetaxel might produce cardiac complications like arrhythmia or heart failure.

FUTURE PROSPECT AND CONCLUSION

Ceftriaxone is a third-generation cephalosporin with strong antimicrobial activity and serves a very vital function in treating numerous types of bacterial infections. By preventing synthesis of the bacterial cell wall via binding to PBPs, ceftriaxone can successfully impair growth of the bacteria, which ends up causing death and cell lysis.

Even with its wide-spectrum activity against both Gram-positive and Gram-negative bacteria, the advent of antibiotic resistance, especially from beta-lactamase-producing organisms, threatens its continued use. Nevertheless, continuous research on combination therapy, the synthesis of newer cephalosporin analogs, and attempts to control resistance are important in maintaining its therapeutic benefit.

In the years to come, the future role of ceftriaxone can be transformed by the evolution of personalized medicine, enhancing dosing regimens and reducing adverse effects. In addition, its ongoing application in global health, particularly in low- and middle-income countries, will continue to be critical to the fight against infectious diseases.

1. Emerging Patterns of Resistance

Challenge of Antibiotic Resistance

The emergence of beta-lactamase-producing bacteria and modifications of PBPs could reduce the efficacy of ceftriaxone.

Future studies are geared towards combating bacterial resistance, for example, the synthesis of ceftriaxone analogs or blends with beta-lactamase inhibitors to circumvent resistance.

2. Combination Therapy

Potential Synergies

Combining ceftriaxone with other drugs may enhance activity against resistant bacteria. Research into fixed-dose combination therapies could maximize the outcome of treatment of multi-drug resistant infections.

3. Wider Spectrum of Activity

Widening Spectrum

Cephalosporins newer or ceftriaxone derivatives are being developed to target a broader group of resistant pathogens.

4. Future Application in Personalized Medicine

Pharmacogenomics

Future use of genetic screening for antibiotic treatment guidance could optimize ceftriaxone efficacy and minimize side effects.

Personalized dosing regimens for improving treatment in patients with varying renal function.

5. Ceftriaxone in New Infections

Potential for New Uses

As new infectious pathogens (e.g., drug-resistant tuberculosis isolates or certain viral infections) emerge, ceftriaxone will be explored for new uses in combination regimens.

New therapeutic uses may be found in future clinical trials.

6. Environmental Sustainability

Environmental Concerns

More research is being conducted about the environmental impact of cephalosporins and their metabolites.

Green production methods and eco-friendly practices in disposing of them will be important in the future to assist in decreasing the environmental harm

B2B	=	Business-to-business
FDA	=	The Food and Drug Administration
ROI	=	Return on investment
HMO	=	Health Maintenance Organization

SUMMARRY

The future of Ceftriaxone, a third-generation cephalosporin, depends on the resolution of upcoming challenges in antimicrobial therapy and keeping it effective in light of emerging bacterial resistance. The following is a summary of the possible developments:

Fighting Antibiotic Resistance

The development of beta-lactamase-producing bacteria and alterations in penicillin-binding proteins (PBPs) are real concerns, diminishing the effectiveness of ceftriaxone. Yet, research into new beta-lactamase inhibitors and combination regimens can revise or renew ceftriaxone's effectiveness.

New analogs or formulations of ceftriaxone could be created to counteract mechanisms of resistance, possibly expanding its range of action and ensuring it remains useful in clinical settings.

Expansion of Spectrum of Activity

Efforts are aimed at expanding ceftriaxone's capacity to act against multi-drug resistant (MDR) organisms. In particular, structural modifications may enhance its efficacy against resistant organisms that are also resistant to previous cephalosporins.

Broadened spectrum may offer additional alternatives in the treatment of infections caused by resistant Gram-negative pathogens and enteric pathogens that are increasingly emerging.

Personalized Medicine and Maximized Dosing

The future developments in pharmacogenomics and biomarker use will enable more tailor-made treatment approaches, with patients receiving the optimal dose of the drug according to their genetic and infection type.

Dosing optimization in patients with different renal function levels will also be a target to reduce side effects and enhance therapeutic efficacy.

Global Health Considerations

Ensuring the availability of ceftriaxone in low- and middle-income nations is important, as it is usually one of the few options available for the treatment of severe infections.

REFERENCE

1. **Pillai, S. K., Moellering, R. C., & Eliopoulos, G. M.** *Antimicrobial Therapy and Resistance.* In J. E. Bennett, R. Dolin, & M. J. Blaser (Eds.), *Principles and Practice of Infectious Diseases* (8th ed., 2012; 3209–3221. Elsevier.
2. **Tamma, P. D., Aucott, J. N., & Millar, E. V.** Ceftriaxone and antibiotic resistance: How can we confront the challenge? *The Lancet Infectious Diseases,* 2020; *20*(7): 689–700. https://doi.org/10.1016/S1473-3099(20)30356-0
3. **Bassetti, M., Righi, E., & Mikulska, M.** New options for treating drug-resistant infections: Focus on third-generation cephalosporins. *Journal of Antimicrobial Chemotherapy,* 2019; *74*(1): 13–20. https://doi.org/10.1093/jac/dky379
4. **Diene, S. M., & Lagier, J. C.** Antibiotic resistance in bacteria: Challenges in treatment and clinical application. *International Journal of Antimicrobial Agents,* 2017; *50*(2): 163–171. https://doi.org/10.1016/j.ijantimicag.2017.01.013
5. **Gupta, R., & Malhotra, S.** Antibiotic resistance: A rising threat to public health. *Journal of Global Antimicrobial Resistance,* 2017; *10:* 92–97. https://doi.org/10.1016/j.jgar.2017.04.002
6. **Nova One Advisor.** (2023). *Ceftriaxone Market Size, Share, Trends & Forecast 2023–2032.* Nova One Advisor Reports. https://www.novaoneadvisor.com/report/ceftriaxone-market

7. **Transparency Market Research.** (2023). *Ceftriaxone Market – Global Industry Analysis and Forecast, 2023–2031.* https://www.transparencymarketresearch.com/ceftriaxone-market.html
8. **RC Market Analytics.** (2023). *Global Ceftriaxone Market Forecast to 2030: Growth Trends, Competitive Landscape & Regional Analysis.* https://www.rcmarketanalytics.com/ceftriaxone-market/
9. **WHO (World Health Organization).** (2021). *Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report, 2021.* https://www.who.int/publications/i/item/9789240027336
10. **Kanj, S. S., & Kanafani, Z. A.** Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended-spectrum beta-lactamase–producing Enterobacteriaceae. *Mayo Clinic Proceedings,* 2011; *86*(3): 250–259. https://doi.org/10.4065/mcp.2010.0674